+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial



Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial



Acta Psychiatrica Scandinavica 104(2): 104-109



Objective: To determine the relative efficacy, tolerability and risk of precipitating mania of moclobemide and imipramine in the treatment of bipolar depression. Method: A randomized, double-blind, parallel group, multicentre study of moclobemide (MCB) (450-750 mg daily) and imipramine (IMI) (150-250 mg daily) in 21 centres in nine countries; 156 patients (65 males, 91 females) aged 18-65 with bipolar depression (17-item Hamilton Depression Rating Scale (HAMD) score gtoreq16) participated. Clinical status was assessed using standardized rating scales before treatment and at 1,2,3,4,6 and 8 weeks. The data were analysed on an intention to treat basis with the last observation carried forward. Results: In the MCB group, the mean HAMD fell from 23.0 to 13.1, in the IMI group it fell from 22.5 to 9.5; the mean score on the Montgomery-Asberg Depression Rating Scale (MADRS) fell from 29.5 to 16.3 on MCB and from 29.2 to 11.6 on IMI. There were no statistically significant differences between the two groups on any efficacy measures. Anticholinergic side-effects were three times more common with IMI than MCB and weight gain was also greater on IMI. Two patients (3.7%) on MCB and six patients (11%) on IMI were withdrawn because of manic symptoms, with manic symptoms occurring earlier on IMI, although these differences did not reach statistical significance. Conclusion: No differences in efficacy were detected between MCB and IMI in the treatment of bipolar depression. The data suggests that MCB is less likely than IMI to precipitate mania.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010993080

Download citation: RISBibTeXText

PMID: 11473503


Related references

A controlled double-blind trial of moclobemide and imipramine in the treatment of depression. Singapore Medical Journal 36(1): 38-40, 1995

Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. International Clinical Psychopharmacology 12(4): 183-193, 1997

Efficacy and Tolerability of Moclobemide Compared with Imipramine in Depressive Disorder (Dsm-Iii): An Austrian Double-blind, Multicentre Study. British Journal of Psychiatry 155(S6): 78-83, 1989

Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial. British Journal of Psychiatry 160: 519-524, 1992

A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. UK Moclobemide Study Group. International Clinical Psychopharmacology 9(2): 109-113, 1994

A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. British Journal of Psychiatry. Supplement 1989(6): 72-77, 1989

A Double-blind Comparative Trial of Moclobemide v. Imipramine and Placebo in Major Depressive Episodes. British Journal of Psychiatry 155(S6): 72-77, 1989

Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium. Acta Psychiatrica Scandinavica. Supplementum 360: 50-51, 1990

Efficacy of tianeptine in the treatment of major depression and depressed bipolar disorders. Illustration of the interest of surveillance of a European multicentre double-blind study in progress: Tianeptine versus placebo and imipramine. European Psychiatry 8(SUPPL 2): 111S-115S, 1993

Moclobemide versus amitriptyline in the treatment of depression: two small double-blind multicentre studies in Belgium. Acta Psychiatrica Scandinavica. Supplementum 360: 52-53, 1990

A double blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Drug Development Research 4(2): 143-154, 1984

Comparative efficacy of antidepressants on anxiety features in depression: A meta-analysis of double-blind studies of imipramine and moclobemide against placebo. International Journal of Psychiatry in Clinical Practice 4(2): 111-117, 2000

Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol). International Journal of Bipolar Disorders 6(1): 11, 2018

Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. American Journal of Psychiatry 149(2): 195-198, 1992

A double-blind multicentre trial comparing mianserin with imipramine. British Journal of Clinical Pharmacology 5 Suppl 1: 87s-90s, 1978